- Q2 2023 Biosyent Inc Earnings Call TranscriptAug 22, 2023$5.54Earnings
- Q1 2023 Biosyent Inc Earnings Presentation TranscriptMay 26, 2023
- Q4 2022 Biosyent Inc Earnings Call TranscriptMar 21, 2023$5.32Earnings
- Biosyent Inc at Issuer Direct Planet MicroCap Showcase (Virtual) TranscriptDec 07, 2022
- Q3 2022 Biosyent Inc Earnings Presentation TranscriptNov 16, 2022
- Q2 2022 Biosyent Inc Earnings Presentation TranscriptAug 23, 2022
- Q1 2022 Biosyent Inc Earnings Presentation TranscriptMay 18, 2022
- Q4 2021 Biosyent Inc Earnings Presentation TranscriptMar 09, 2022
- Q3 2021 Biosyent Inc Earnings Call TranscriptNov 18, 2021$5.71Earnings
- Q2 2021 Biosyent Inc Earnings Call TranscriptAug 25, 2021$6.12 (-2.99%)Earnings
- Q1 2021 Biosyent Inc Earnings Call TranscriptMay 27, 2021$6.19Earnings
- Biosyent Inc Annual Shareholders Meeting TranscriptMay 26, 2021
- Q4 2020 Biosyent Inc Earnings Call TranscriptMar 17, 2021$5.76 (-1.71%)Earnings
- Q3 2020 Biosyent Inc Earnings Call TranscriptNov 26, 2020Earnings
- Q2 2020 Biosyent Inc Earnings Call TranscriptAug 26, 2020$5.24 (+0.13%)Earnings
- Q1 2020 Biosyent Inc Earnings Presentation TranscriptMay 28, 2020
- Q3 2019 Biosyent Inc Earnings Call TranscriptNov 20, 2019$4.99 (+13.41%)Earnings
- Q2 2019 Biosyent Inc Earnings Call TranscriptAug 23, 2019$4.52 (-9.60%)Earnings
- Q1 2019 Biosyent Inc Earnings Call TranscriptMay 29, 2019$5.84 (-3.15%)Earnings
- Q4 2018 Biosyent Inc Earnings Call TranscriptMar 20, 2019$6.2 (+0.81%)Earnings
Q4 2022 Biosyent Inc Earnings Call Transcript
© -
Hello, and welcome to the BioSyent, Inc. Q4 and Full Year Fiscal 2022 Results Presentation. My name is René Goehrum, and I'm the President and CEO of the company. Before I start the presentation, I want to bring your attention to our disclaimer on forward-looking statements. And I'll jump right into the presentation by looking at the Q4 revenue, EBITDA and net income after tax.
So you can see sales were just short of $7.5 million for the quarter. That was up 3% to the year ago. And I want to go into a little bit of detail to help you follow the moving parts on revenue. So in the quarter, the Canadian Pharmaceutical business was up 13% to the year ago. The International Pharma business down 63%, and the Legacy Business down 87% in the quarter. You'll recall that late last year, we discontinued products effective the beginning of 2022, I should say late last year as in 2021, the comparable period. And so when we're looking at revenue for Canada and overall, it is useful to also compare to a continuing business basis. And
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)